Approximately 1% of the global population is affected by intellectual disability (ID), and the majority receive no molecular diagnosis. Previous studies have indicated high levels of genetic heterogeneity, with estimates of more than 2500 autosomal ID genes, the majority of which are autosomal recessive (AR). Here, we combined microarray genotyping, homozygosity-by-descent (HBD) mapping, copy number variation (CNV) analysis, and whole exome sequencing (WES) to identify disease genes/mutations in 192 multiplex Pakistani and Iranian consanguineous families with non-syndromic ID. We identified definite or candidate mutations (or CNVs) in 51% of families in 72 different genes, including 26 not previously reported for ARID. The new ARID genes include nine with loss-of-function mutations (ABI2, MAPK8, MPDZ, PIDD1, SLAIN1, TBC1D23, TRAPPC6B, UBA7 and USP44), and missense mutations include the first reports of variants in BDNF or TET1 associated with ID. The genes identified also showed overlap with de novo gene sets for other neuropsychiatric disorders. Transcriptional studies showed prominent expression in the prenatal brain. The high yield of AR mutations for ID indicated that this approach has excellent clinical potential and should inform clinical diagnostics, including clinical whole exome and genome sequencing, for populations in which consanguinity is common. As with other AR disorders, the relevance will also apply to outbred populations. 2 The clinical presentation and aetiology of ID are complex and highly heterogeneous, thus leading to a poor rate of molecular diagnosis and inadequate clinical management and counselling.
INTRODUCTION
Approximately 1% of the global population is affected by intellectual disability (ID), 1 which can have a devastating effect on the lives of the affected individuals and their families and is a major challenge at the clinical level. Genetic factors are involved in the aetiology of 25-50% of ID cases. 2 The clinical presentation and aetiology of ID are complex and highly heterogeneous, thus leading to a poor rate of molecular diagnosis and inadequate clinical management and counselling.
ID can be divided into two groups: syndromic (S) ID, in which comorbid illness or physical features are present, and nonsyndromic (NS) ID, in which no obvious comorbidities are present. Of 700 known ID genes (S and NS), fewer than 50 genes are mutated in NS autosomal recessive ID (NS-ARID).
2 X-linked ID may account for only 10-12% of ID cases.
3 Dominant autosomal variants occurring de novo may contribute to a large proportion of sporadic cases, particularly in outbred populations. [4] [5] [6] Autosomal recessive (AR) variants also play a significant role in ID, because recessive variants can remain hidden in the population in heterozygous form. Estimates have suggested that there may be 42500 autosomal ID genes in total-the majority being recessive. 7 In populations with high levels of consanguinity, most ID-causing mutations are recessive. 7 Even in outbred populations, 13-24% of ID cases have been estimated to be due to autosomal recessive causes. 7 Despite an increased diagnostic yield among those who receive testing, 2 currently, the majority of individuals with ID receive no molecular diagnosis 8 -a shortcoming that can affect health and lifespan. Recent studies have indicated that the median age of death is 13 years younger for males with ID and 20 years younger for females with ID than in the general population. 9 Although advances in genotyping and sequencing technology have accelerated the rate of gene discovery for ID, 10 the majority of ID genes remain undetected. However, large-scale ID family studies are making significant inroads. 11 Homozygosity mapping has been proven to be an effective method for gene identification in consanguineous populations. [11] [12] [13] [14] [15] [16] [17] Consanguineous marriages lead to a marked increase in the frequency of severe recessive disorders. 18 Collectively, countries with levels of consanguinity higher than 10%, mainly in Africa, the Middle East and South Asia, 19, 20 represent a population of~1.3 billion. In Pakistan, 62.7% of the population engages in consanguineous marriages, of which~80.4% are first-cousin marriages. 21 The rate of consanguineous marriages in Iran is estimated at 40%. 22 Here, we present a study of multiplex ID families from Pakistan (N = 176) and Iran (N = 16) using microarray-based genotyping to identify autozygous regions (HBD shared by affected family members), coupled with whole exome sequencing (WES) to identify causal variants (see Figure 1 for workflow). In total, we identified single candidate genes/variants in 88 families (50% were loss-of-function (LoF) mutations), and 10 candidate pathogenic genomic variants (CNVs) in nine families.
MATERIALS AND METHODS

Family recruitment
Institutional research ethics board consent was given for the study by the Centre for Addiction & Mental Health, Toronto, as well as by the institutes at the recruiting sites (details in the Supplementary Methods). Families were recruited on the basis of diagnosis of ID in more than one individual (or ID and/or learning disability for N = 13 families; or both ID and psychosis within the family, N = 5) but with no obvious dysmorphic features or comorbidities, and with parental consanguinity. Typically marriages were Figure 1 . Microarray and exome sequencing work flow. CNV, copy number variations; HBD, homozygosity-by-descent; WES, whole exome sequencing.
first-or second-cousin marriages; however, in a number of families, the exact relationship between the parents could not be established, but the marriage was within the same clan or caste. Written informed consent was obtained from all participants. Blood was drawn, and genomic DNA was extracted by standard methods. Cases of fragile X (tested using established methods 23, 24 ), Down's syndrome and other clearly recognisable syndromes were excluded. Summary statistics for the families are given in Table 1 .
Autozygosity mapping
Autozygosity mapping was performed using microarray data from the Illumina Human CoreExome, Affymetrix Mapping 500 K NspI, Affymetrix CytoScan HD and Affymetrix SNP 5.0 or 6.0. All genotyping was performed according to the manufacturer's protocol, and data were processed using either the Affymetrix Genotyping Console (500 K and 5.0), Affymetrix ChAS Software Suite (CytoScan HD and SNP 6.0) or the Illumina GenomeStudio platform (Illumina CoreExome). All data were exported to PLINK format for analysis using HomozygosityMapper 25 and FSuite. 26 Details are provided in Supplementary Methods.
CNV analysis
CNV analysis was performed to identify homozygous CNVs in HBD regions or heterozygous likely pathogenic CNVs that could indicate cases of intra-familial genetic heterogeneity, which were then excluded from the HBD/WES analyses (details in Supplementary Methods).
Whole exome sequencing WES was performed for one or more affected member from each family, using sequencing facilities at CAMH, Toronto. Three different nextgeneration sequencing platforms were used across the study, taking advantage of newer platforms as they became available for research at CAMH (SOLiD 5500 platform (Life Technologies) for 49 families (51 individuals), using a protocol reported previously; 27 Ion Proton platform/Ion Ampliseq Exome kit (Life Technologies) for 49 individuals from 30 families; Illumina HiSeq2500 platform, using ThruPLEX DNA-seq 96D kit (Rubicon, R400407) and SureSelect XT2 Target Enrichment (Agilent Technologies) system for 150 families).
Sequencing alignment and variant calling
We used an in-house pipeline to map and call variants on the different types of sequencing data for this study. The pipeline is summarised in Supplementary Figure 1 and in Supplementary Methods.
After putative variants were identified, Sanger sequencing was used to validate the variants and determine whether the variant segregated with the disease by testing the parents and other affected and unaffected individuals within the family.
Gene list construction
We combined the genes listed in Supplementary Table 3 with other genes for X-linked or autosomal recessive intellectual disability/mental retardation in OMIM. This full list is available as Supplementary Table 7 . This gene list was used in the pathway and gene expression analyses (details in Supplementary Methods).
Database searches across different neuropsychiatric and neurodevelopmental disorders and functional and animal models We compared our variants to several databases including EpilepsyGene, Gene2Phenotype, Gene2Cognition, Schizophrenia Genebook, published disease-specific gene-sets, 6 HGMD, 28 OMIM, 29 Zfin, 30 targets of FMRP through high-throughput sequencing of RNAs by cross-linking immuneprecipitation (HITS-CLIP) 31 and Mouseportal (http://www.sanger.ac.uk/ science/collaboration/mouse-resource-portal, accessed May 2016). Searches were performed to identify genes/variants overlapping with our dataset. 36 MAN1B1). 37 Likely pathogenic CNVs were identified in at least nine families (not including the VPS13B and TUSC3 deletions in AN51 and AN21, respectively).
RESULTS
Our
Homozygous loss-of-function Mutations Homozygous truncating LoF mutations were found as single candidate variants in 43 families, including nine genes that had not been previously described in relation to NS-ARID: ABI2, MAPK8, MPDZ, PIDD1, SLAIN1, TBC1D23, TRAPPC6B, UBA7 and USP44. None of these genes have been noted as tolerant to loss of function through WES of 3222 British adults of Pakistani origin. 38 We identified the same nonsense mutation in PIDD1 in two unrelated Pakistani families (ASMR105 and ASMR110; Figure 2 ). PIDD1 encodes p53-Induced Death Domain Protein (PIDD; MIM 605247), and Gln863* disrupts the death domain (DD), through which PIDD1 interacts with other DD proteins such as RIP1 or CRADD/RAIDD. Truncating mutations in CRADD have previously been reported for NS-ARID (MRT34; MIM 614499), 39 and thus our findings support the involvement of PIDD-related pathways in the aetiology of ID.
Homozygous truncating mutations in TRAPPC9 have been reported for NS-ARID; 12, 36, [40] [41] [42] [43] thus it is notable that we identified a nonsense mutation in TRAPPC6B, which encodes a second member of the same protein trafficking particle complex.
A nonsense mutation was identified in SLAIN1 that segregated fully in family PK68 (Figure 2 ). SLAIN1 and SLAIN2 encode microtubule plus-end tracking proteins that have been shown to be crucial for normal axonal growth in developing hippocampal neurons. 44 We report here a homozygous nonsense mutation in the gene UBA7 in family PK34. UBA7 encodes ubiquitin-activating enzyme 7, which is believed to be involved in the ubiquitin conjugation pathway. 45 Family PK34 is one of three families in the study that did not meet the criteria for ID and instead were reported as having learning disorders and were considered relatively high functioning. We also report that this variant is present at a relatively high frequency in the South Asian population (MAF = 0.0054; ExAC database), and two homozygotes for this variant were among the control group. Thus, this variant and gene may be a risk factor for a much milder form of cognitive disability and thus may potentially be present in the control South Asian population (N48000) used in the ExAC database.
We also identified a LoF mutation in TMEM135, which has previously been reported in a large Iranian NS-ARID cohort by Najmabadi et al., 11 (in which a missense mutation, Cys228Ser, was reported), and in Wright et al., 46 (missense), as a quantitative trait locus associated with intelligence. 47 
Missense mutations
We identified homozygous missense variants as single candidate variants in 43 families, including 16 for which the identified genes have not previously been reported for NS-ARID (AFF3, BDNF, CAPS, DMBT1, DUOX2, EXTL3, FBXO47, LAMC1, MAP3K7, SDK2, SPATA13, SUMF2, SYNRG, TET1, VPS35 and ZBTB11). Although LoF mutations are frequently more convincing than missense mutations, a number of the homozygous missense changes reported here are of particular interest, owing to the known nature or function of the protein or the likely effect of the amino acid substitution on protein function. For instance, we report a homozygous missense change Met122Thr in the gene for brain-derived neurotrophic factor, BDNF, which has been implicated in many studies of neuropsychiatric disorders 48 and is a known gene target of MECP2, the Rett syndrome gene. 49, 50 This variant replaces a methionine, a large, non-polar residue with an S-methyl thioether side chain, that is fully conserved across the vertebrate lineage with threonine, a small, polar residue with a hydroxyl side chain. This variant is present with a frequency of 0.0001647 in ExAC (in South Asians MAF = 0.001211) with no homozygotes and has not previously been reported in any publications. The BDNF protein is important for the survival, differentiation and development of neurons in the central nervous system. Hence, the identification of Met122Thr in connection with cognitive disability is likely to be of great interest, and functional studies of the effects of Met122Thr on BDNF function are warranted.
We detected a homozygous Lys2056Asn change in TET1 in family PK70 that is not present in any variant or mutation databases. Methylcytosine dioxygenase TET proteins play a role in the DNA methylation process and gene activation, and TET1 is an important regulator of neuronal differentiation. TET1 has been implicated in schizophrenia (SCZ) and bipolar disorder by downregulation of the expression of GAD1, RELN and BDNF genes through epigenetic mechanisms in the prefrontal cortex and in the cerebellum in autism. 51, 52 Significant upregulation of TET1 messenger RNA (mRNA) in the parietal cortex of psychosis patients has also been reported. 53 Tet1 knockout results in impaired hippocampal neurogenesis, cognitive deficits in mice, 54 Abbreviations: HBD, homozygosity-by-descent; ID, intellectual disability. Families AS105 and AS110 both carry the same mutation in PIDD1 and share a common haplotype; however, these families are apparently not closely related. Using Prest-plus 81 to estimate IBD using Maximum Likelihood Estimation, it was confirmed that the two families are separated by at least four generations, which is comparable to relatedness in the background population, and thus AS105 and AS110 are considered unrelated. na = not applicable, because Iranian exome data are not available in the ExAC database. A list of all variants identified including known syndromic ARID or XLID genes identified in the cohort are given in Supplementary Table 3a; Supplementary Table 3b The MPDZ mutation reported here is not within a significant region of HBD and is present as homozygous in the affected mother and the first-born affected son. The affected brother and sister are both heterozygous, but the father is wild type homozygous, thus suggesting non paternity for the first child.
and abnormal brain morphology in zebrafish. 55 The large basic, charged, hydrophobic lysine residue at this position is conserved in mammals (or as glutamic acid in non-mammalian vertebrates) and is replaced in this variant by the small polar asparagine residue.
The homozygous His880Gln change identified in the zinc finger/BTB domain gene ZBTB11 in family AN50 disrupts a canonical Zn 2+ -binding residue in one of the zinc fingers and is likely to result in an alteration in the specificity of DNA-binding/ gene regulation. AFF3 is an autosomal homologue of the X-linked ID gene AFF2 (MRX-FRAXE; MIM 309547). As with AFF2, AFF3 is also associated with a fragile site (FRA2A) in which expansion of a CGG trinucleotide repeat triggers hypermethylation and gene silencing in association with neurodevelopmental disorders. 56 The Gly1215-Val variant identified here is located within a five-amino acid C-terminal motif (Gln-Gly-Leu-His-Trp) that is highly conserved across the vertebrate lineage.
In family AS70, a missense mutation was identified in exon 12 of the gene MAP3K7. Although missense mutations in this gene have recently been reported for frontometaphyseal dysplasia 57 and cardiospondylocarpofacial syndrome, 58 members of family AS70 have no skeletal dysplasia or obvious dysmorphic features, thus suggesting even greater pleiotropy of this gene. We note that although the Arg410Gln mutation identified is located in exon 12, which is alternatively spliced and present in both transcripts B and C but neither A nor D, all MAP3K7 mutations reported to date for frontometaphyseal dysplasia or cardiospondylocarpofacial syndrome are located in canonical exons (i.e., in all four transcript variants). Furthermore, analysis of mouse RNAseq data from the ENCODE UW project (through UCSC Genome Browser) suggests that although exon 12 is expressed in many adult tissues, including the brain, it is absent from skeletal muscle.
Families with multiple variants For 11 additional families, between two and four putative damaging variants were identified after filtration that fulfilled the criteria and segregated in the families; however, without functional evidence in support of pathogenicity, it is not possible to narrow these variants to a single candidate (Supplementary Table 3B ).
X-linked variants A number of the families were compatible for both AR and X-linkage, and several variants or CNVs on the X chromosome were identified, including two variants in ATRX and a 6.7-Mb interstitial duplication on Xp22.31-p22.2.
We report a missense mutation, Ser57Pro, in the X-chromosomal gene MAGEA11, segregating in family PK87. A Gln4Arg variant in MAGEA11 has recently been reported among a cohort of X-linked ID families.
59 MAGEA11 shows protein interaction with TRMT1-also reported here for NS-ARID-as determined by yeasttwo-hybrid analysis. [60] [61] [62] In another large multiplex and multi-branch family, the missense mutation Arg190His of the X-linked MECP2 gene is present in hemizygous form in a single male with mild ID and in heterozygous form in several females with mild ID or mild ID with psychosis or depression. Interestingly, for the female heterozygotes with ID, all appeared cognitively normal until the age of~9 years, when cognitive regression started, and for the single male hemizygote, cognitive regression began much earlier, at o 5 years of age. The family also has several males with SCZ, with onset at 18 years but without cognitive regression amounting to ID, who are wild type for this variant (Supplementary Figure 2) . The Arg190 residue is a critical DNA-binding amino acid within an AT-hook The affected individual in AS114 with FMN2 mutation is a genocopy, and the genes/mutations in the other four affected individuals in this pedigree have yet to be established. The homozygous nonsense mutation in TUSC3 is not in a shared HBD region and does not segregate with other affected members of family PK11. The missense change in GPT2 is also predicted to affect a splice donor site (BDGP (www.fruitfly.org) splice predictor score: WT: 0.78; mut: 0.58).
Mapping autosomal recessive intellectual disability genes R Harripaul et al domain, and a de novo mutation at this residue, Arg190Cys, has been reported in a SCZ patient. 63 Genes with 'hits' in multiple families Confidence in gene discovery relies on the identification of multiple affected families with mutations in the same gene and/or replication in further studies. However, owing to the anticipated high degree of genetic heterogeneity in NS-ARID, large sample sizes are typically required to include multiple families with mutations in the same gene. Comparison across different studies is thus vital. Of the ARID genes reported here for we believe the first time, several are conspicuous because of the presence of mutations in multiple families. In our study, the same nonsense mutation in PIDD1 was observed in two apparently unrelated Pakistani families. We also provide confirmatory families/mutations for recently reported ARID genes such as C12ORF4, CCDC82, MBOAT7, IMPA1, TMEM135, PGAP2, GPT2 (2 families), TDP2 (2 families) and GMPPA (Table 3, and  Supplementary Table 3 ). In addition, mutations in the gene for IDassociated brain malformation polymicrogyria, GPR56, are present in three families in this study and thus may represent a relatively large proportion of ID families in these populations.
Families with mutations in previously identified genes for metabolic or hormonal disorders We report three mutations in the thyroid dyshormonogenesis genes thyroid peroxidase (TPO), thyroglobulin (TG) 64 , and thyroid 65 and in a patient with a mild holoprosencephaly spectrum phenotype. 66 An overlapping but slightly proximal deletion (~chr2:114188161-119321989) has been reported to be compatible with a normal phenotype. 67 In one family, PK28, all three affected males in one branch were shown to have a large (6.7 Mb) interstitial duplication spanning cytobands Xp22.31-p22.2.
For homozygous CNVs in HBD regions, we identified homozygous deletions in known ARID genes in several families (Table 3;  Supplementary Table 3) , including a 170 kb homozygous deletion spanning 9 of 10 exons of the NS-ARID gene TUSC3 in family AN21 [ref. 68] and a 51 kb deletion spanning exons 37-40 of the Cohen syndrome gene, VPS13B, in family AN51. 69 Homozygous disrupting loss CNVs included a 50 kb deletion spanning exons 2 and 3 of RAB8B in PK95-7; however, this deletion was not in a shared HBD region and was thus considered a potential case of intra-familial genetic heterogeneity.
Databases for neuropsychiatric disorders Genes relevant for ID are also frequently identified in individuals with autism spectrum disorders (ASD) and epilepsy (both of which frequently also present with ID). In addition, there is growing support for overlap of ID genes with genes affecting other neuropsychiatric disorders. 70 For example, genes such as NRXN1 and ANK3, which have been linked with SCZ, BD and ASD by CNV and/or genome-wide association studies, are also known ARID genes (NRXN1: PTHLS2, MIM 614325; ANK3: MRT37, MIM 615494). For this reason, we attempted to evaluate the genes identified here in variant databases or among lists of genes associated with such disorders. We screened various epilepsy or neuropsychiatric disease-specific databases or published datasets for the presence of variants in these genes. In the SCZ/control exome sequence database Genebook, 71, 72 none of the identified variants in Table 2 were present. However, for several of the genes, an increased burden of rare variants has been reported in SCZ cases versus controls (P o0.05 for VPS35, SYNRG, DMBT1, ALPI and NEU4; P o0.002 for SLC13A5), although when corrected for multiple testing, no individual gene-based tests achieved statistical significance.
In epilepsy databases, we identified ATRX, MECP2, SLC13A5 and ST3GAL3, all of which have been reported in cases of epilepsy as well as ID. These four genes are either inherited as autosomal recessive or X-linked recessive. ATRX and MECP2 proteins interact with each other and are involved in chromatin binding and gene regulation, 73 and mutations in either gene can have diverse effects on DNA methylation patterns and brain development.
Protein interaction analysis
We used BioGrid (http://thebiogrid.org) to identify protein interactors for each of the 67 different ARID genes identified among our population (Supplementary Table 3A) , as well as GRIN2B (Supplementary Table 3C ). Interacting proteins are listed, along with gene ontology processes, functions and cellular compartments, in Supplementary Table 5 .
Pathway analyses
In agreement with past findings of genetic heterogeneity, we observed limited overlap with the gene ontology gene sets. Of the 14,312 sets tested, 16 survived multiple test correction (q-valueo0.05), and a few top-ranked terms are of interest (Supplementary Table 6 ). Protein glycosylation, which is known to be associated with ID, was ranked sixth with nine overlapping genes (corrected Po0.05). As mentioned above, TPO, DUOX2 and TG are known to be involved in thyroid hormone generation (rank: 14, corrected Po0.05). The smoothened signalling pathway was ranked thirty second with four overlapping genes (NDST1, CC2D2A, TCTN2 and BBS7).
Anatomical expression analyses
With the exception of the spinal cord, all neural tissues were enriched in the expression of the ID genes (corrected P o0.0001, Supplementary Table 8 ). The frontal cortex was the most enriched, with 1.4 times the expected number of expressed genes. Although the brain expressed a majority of all genes, the ID genes appeared to show specificity. Of the 17 fetal tissues tested, the ovary and testis had the highest number of expressed genes but did not show enriched expression of the ID genes (corrected P40.12).
Developmental brain expression analyses
Across the developmental transcriptome, ID genes were expressed at higher levels in the normal prenatal brain (Figure 3 ). The amygdaloid complex showed the most consistent enrichment (five specimens with significantly higher expression of ID genes). Fetal brain samples from 21 and 24 weeks postconception showed the highest number of regions with significant expression (44 or more). By contrast, enriched expression was not observed in the postnatal brain samples. This prenatal pattern found in exon microarray expression profiles was also observed in RNA sequencing measurements in a largely overlapping set of samples from the same resource (BrainSpan, Supplementary Figure 3) . The RNA sequencing measurements showed donor-specific patterns with many enriched regions. These global patterns were not consistent across donors of the same age, thus suggesting that the RNA sequencing data may have normalisation artefacts not present in the microarray measurements. Grouping the ID gene list into genes associated with glycosylation or hormones and metabolism revealed aboveaverage prenatal expression for all groupings (Figure 3) . Genes with metabolic or hormonal-associated function had the most stable trajectory. We also observed higher expression for those groups in the prenatal brain in the BrainCloud 74 resource, which assayed the prefrontal cortex across human development (Supplementary Figure 4) . , primary motor cortex (area M1, area 4) (M1C), primary somatosensory cortex (area S1, areas 3,1,2) (S1C), primary auditory cortex (core) (A1C), primary visual cortex (striate cortex, area V1/17) (V1C), hippocampus (hippocampal formation) (HIP), amygdaloid complex (AMY), mediodorsal nucleus of thalamus (MD), striatum (STR) and cerebellar cortex (CBC). ID, intellectual disability. which 50 new genes for NS-ARID were reported, of which 40% had LoF mutations. In general, LoF mutations provide a higher degree of confidence of disease association than missense mutations.
There are a number of likely reasons that genes/mutations were not found for some families: (1) intra-familial aetiologic heterogeneity; (2) poor WES depth of coverage at the aetiologic gene/ mutation; (3) intronic or intergenic causative mutations, which are not detected by WES. Whole genome sequencing may address this issue; (4) Common variants have been reported in association with many complex diseases, including traits such as intelligence or cognitive ability. 75, 76 It is plausible that a proportion of ID cases with familial aggregation are caused by variants, possibly interacting, that are common in the general population but have low penetrance. These variants together could potentially cause ID; however, this hypothesis has not been explored in ID. (5) Nongenetic factors may be prevalent in some families, for example, prenatal or perinatal insult. 77 Given that there may be an overlap in the genetic aetiology of neurodevelopmental and neuropsychiatric disorders, we crossreferenced our ID gene list with those from studies of other neuropsychiatric/neurodevelopmental disorders. Many genes identified for ARID have been implicated across disorders (Figure 4 ). For instance, of the newly identified genes, SLAIN1 has been listed as one of the top-ranked genes for the burden of variants among a large cohort with SCZ (N = 1392). 78 Data from the Autism Sequencing Consortium 79 have revealed de novo LoF mutations in SPATA13 and TBC1D23, as well as de novo missense mutations in ABI2, TET1, and SYNRG. Li et al., 80 reported variants in both MPDZ and SPATA13 in ASD cohorts and a de novo missense variant in MAPK8 in SCZ. 72 In addition, whereas heterozygous (typically de novo) mutations in SCN1A have been linked with ASD, ID, and epileptic encephalopathy, the missense SCN1A variant reported here is homozygous. A number of ARID genes (e.g., NRXN1, CNTNTAP2 and ANK3) have already been implicated in neuropsychiatric disorders by GWAS or CNV studies (as heterozygous). We speculate that, in addition to pleiotropy with other neuropsychiatric/neurodevelopmental disorders, the mode of inheritance may also be variable, (e.g., SPATA13: homozygous missense variant in ID (this study) and de novo LoF variant in ASD; 80 HNMT: homozygous missense variant in ID 17 and heterozygous splice mutation in SCZ (Genebook)). ID may be conceptualised as a much more severe form of neurodevelopmental disorder than ASD and SCZ.
Transcriptional analysis of our gene set combined with known ARID genes revealed greater levels of transcription in the prenatal brain than the postnatal or adult brain (Figure 3a) and, in particular, higher levels in the frontal cortex, hippocampus and amygdala (Figure 3b) . ID is primarily a disorder of brain development, and thus it was reassuring to observe relevant patterns of spatiotemporal expression of ID genes. Pathway analysis of the gene set showed several significant pathways; thyroid metabolism was prominent, as was protein glycosylation and the Smoothened signalling pathway. This and other studies have predicted involvement of numerous different pathways in ID, which is probably a reflection of the high genetic heterogeneity in ID.
Our findings and those of other groups studying the genetics of NS-ARID should be invaluable for the development of targeted sequencing gene panels for diagnostic screening and for the development of clinical whole exome and whole genome sequencing. In this regard, both the replication of previous findings and new discoveries in this study are important. Replication enhances the confidence in the validity of findings, and new discoveries provide opportunities for further exploration of the functions and biological pathways of the newly associated genes. Cumulatively, such studies have also mapped genes across the human genome in which LoF mutations are viable, and the roles of these genes in human development are thus likely to be amenable to further study and comparison with similar mutations in model organisms. Furthermore, a more comprehensive picture is being assembled of the molecular components and mechanisms that are important for the development of a fully functioning central nervous system, as well as the points in the mechanisms that are most vulnerable to genetic mutation. Through comparison with similar studies, we also note that many more such discoveries are needed to complete the picture. The ultimate challenge, to devise targeted therapeutic strategies for ID patients, is thus a step closer.
The discovery of disease-causing mutations in consanguineous families immediately creates opportunities for carrier screening among relatives and prevention of ID, thus providing a direct benefit to the families, communities, and to public health. In addition, the identification of genetic causes for ID allows individuals with ID to be subgrouped on the basis of gene or pathway. This categorisation can lead to the development of cohorts that can then be studied prospectively for the natural course of the disease and health complications and that can also be targeted for therapeutic strategies, thus representing a step towards personalised medicine in this important clinical population.
